Tech Company Financing Transactions
Design Therapeutics Funding Round
On 3/25/2020, Design Therapeutics received $45 million in Series A funding from SR One Capital Management, Cormorant Asset Management and Quan Capital.
Transaction Overview
Company Name
Announced On
3/25/2020
Transaction Type
Venture Equity
Amount
$45,000,000
Round
Series A
Investors
SR One Capital Management (Lead Investor) (Simeon George)
Proceeds Purpose
With the use of proceeds from the Series A fundraising, Design Therapeutic intends to conduct IND-enabling studies and initiate clinical development for its program for Friedreich's ataxia.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
6005 Hidden Valley Rd. 220
Carlsbad, CA 92011
USA
Carlsbad, CA 92011
USA
Phone
Undisclosed
Website
Email Address
Overview
Design Therapeutics is a biotechnology company developing a new class of therapies for serious degenerative disorders caused by nucleotide repeat expansions. The company's lead program is focused on the treatment of Friedreich's ataxia and discovery efforts are ongoing in other degenerative diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Pratik Shah
Chief Executive Officer
João Siffert
Chief Operating Officer
Sean Jeffries
Co-Founder
Aseem Ansari
Browse more venture capital transactions:
Prev: 3/25/2020: ClinOne venture capital transaction
Next: 3/26/2020: SecondNature venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. All VC database entries reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs